Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Our approach
Proprietary Technology
NeoVAC, our main product in development, which is aimed to enter the clinic in 2020, is developed utilizing our proprietary PersoVax™, AmpliVax™, Pyrovant™ and CADVax™ technologies.
Unique Differentiators
DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide/RNA vaccines, or cell-based immunotherapies.
Company Highlights
About Us
Company Background
Immunetune, based in Leiden, the Netherlands, is a dedicated and fast-moving biotech company committed to develop personalized, tumor-specific vaccines to fight cancer and prevent its recurrence.
News
Immunetune in Top 25 of Health in Blue Tulip Awards 2020!
Immunetune is proud to have been selected as one of the Top 25 of the 2020 Blue Tulip Awards in the category Health! Click here for more information.
Neoantigen Summit Europe, April 7-9 in Amsterdam
CEO Gerben Zondag will present Immunetune's unique platform that enables time- and cost-efficient generation of personalized, DNA-based cancer vaccines at the upcoming Neoantigen Summit Europe, 7-9 April in Amsterdam.
Immunetune featured in Biotech News & Life Science
Immunetune was featured in the December 2019 issue of Biotech News & Life Science, read the full article here (in Dutch only).